Skip to content

Comparison of lumbar interbody fusion under OSE and UBE and traditional posterior lumbar interbody fusion (TLIF): a prospective study

Comparison of lumbar interbody fusion under OSE and UBE and traditional posterior lumbar interbody fusion (TLIF): a prospective study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057969
Enrollment
Unknown
Registered
2022-03-24
Start date
2022-03-25
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar spinal stenosis

Interventions

Group A:Traditional posterior lumbar interbody fusion
Group B:OSE for lumbar intervertebral fusion
Group C:UBE for lumbar intervertebral fusion

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The patient had typical symptoms, excluding other diseases caused; 2. The patient's preoperative imaging data were complete, suggesting single-segment lumbar spinal stenosis, and the symptoms were consistent with imaging; 3. The patient has obvious lumbar spondylolisthesis or lumbar instability; 4. The patient underwent active surgery after a certain period of conservative treatment was ineffective.

Exclusion criteria

Exclusion criteria: 1. Patients with lumbar disc herniation other than the above types (such as extreme lateral lumbar disc herniation, calcification of intervertebral disc and posterior longitudinal ligament, local anatomical variation, developmental lumbar spinal stenosis, severe local adhesion and recurrence after the same space); 2. Pregnant or lactating women; 3. Patients with severe heart, liver, and kidney diseases; 4. Patients who are participating in other clinical trials; 5. Patients who do not agree to participate in the study or are unwilling to abide by the blind method of the study; 6. Patients the researchers considered unsuitable for clinical trials for other reasons.

Design outcomes

Primary

MeasureTime frame
Interbody fusion rate;

Secondary

MeasureTime frame
Visual analogue scale;The oswestry disability index;Peri-operative bleeding;Operative time;C-reactive protein;Japanese orthopeadic association score;

Countries

China

Contacts

Public ContactHaipeng Si

Qilu Hospital of Shandong University

18560082571@163.com+86 18560082571

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026